SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format ...

STRO-004 (tissue factor ADC) preclinical data has demonstrated greater anti-tumor activity and lower toxicity compared to a benchmark tissue factor ADC Preclinical models highlight potent anti-tumor ...

Net Product Revenue (Q2 2025): $18.1 million, up from $17 million in Q2 2024. Net Product Revenue (First Half 2025): $35.5 million, compared to $34.9 million in the first half of 2024. Restructuring ...

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted ...

ADC Therapeutics Ltd ( (ADCT)) has released its Q3 earnings. Here is a breakdown of the information ADC Therapeutics Ltd presented to its investors. ADC Therapeutics, a commercial-stage leader in ...

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent ...

Data highlights the ability of Akari’s Trop2 ADC, AKTX-101, to kill K-Ras G12V mutated cancer cell lines in preclinical models, potentially addressing one of the most lethal cancers with the lowest ...

-Encouraging Phase I Data from Two ADC Programs Utilizing Seattle Genetics' Technology- "Genentech's phase I data and their advancement of these two ADCs into phase II clinical development, as well as ...

(MENAFN- GlobeNewsWire - Nasdaq) - Company has initiated Phase 1 study with STRO-004, its potential best-in-class Tissue Factor ADC - - Sutro has selected PTK7 as the target for its initial ...